“The DEA: Four Decades of Impeding and Rejecting Science,” released by the Multidisciplinary Association for Psychedelic Studies (MAPS) and DPA, calls on the Drug Enforcement Administration (DEA) to end its “unjustifiable” monopoly of the supply of research grade marijuana available for federally approved research.
According to the report, the DEA has maintained marijuana’s classification as a harmful drug with no medical benefits despite scientific evidence to the contrary and has also obstructed research that could lead to the substance’s reclassification.
“The DEA impedes research by abusing its discretionary powers over the scheduling process, making it difficult to obtain marijuana for research purposes. We recommend taking away the DEA’s power over drug scheduling and access to drugs for research,” Ethan Nadelmann, executive director of the DPA.
The DEA has ignored calls to reschedule marijuana, which is currently called a ‘Schedule 1’ drug meaning it has no known medical value and is on par with drugs like heroin and crack.
“The DEA has created a Catch-22 — saying that the FDA didn’t approve marijuana therefore it’s bogus, while at the same time obstructing FDA research necessary for approval,” Jag Davies, publications manager for DPA, said. He added that no other drug is treated like marijuana, which is available only from a single government source, the DEA, for research purposes.
“The notion that the DEA has not thought about reconsidering scheduling of marijuana seems to be against scientific evidence and what we’re trying to do as a society that relies on empirical evidence to make decisions,” Hart added.
While the DEA continues to argue there is insufficient evidence to support rescheduling marijuana, it systematically impedes scientific research that could prove otherwise, the report said.
Read Full Story On: aljazeera